ABBV-969 is a Dual-Targeted ADC for PSMA-Low mCRPC
The correct answer is D: ABBV-969 is a dual-targeted ADC binding PSMA and/or STEAP1, designed to address antigen heterogeneity and potentially benefit patients regardless of PSMA/STEAP1 expression alone. This patient with PSMA-low disease on PET imaging who has exhausted standard therapies represents an ideal candidate for this novel dual-targeting strategy.
Why This Matters for Your Patient
Your 72-year-old patient presents a challenging clinical scenario—heavily pretreated with progression through two ARPIs, docetaxel, cabazitaxel, and lutetium PSMA-617, with PSMA-low tumors. According to current ASCO guidelines 1, he has limited remaining options (cabazitaxel plus carboplatin, radium-223 if bone-only symptomatic, or best supportive care). The PSMA-low status makes him a poor candidate for additional PSMA-directed therapies but potentially well-suited for ABBV-969.
Understanding ABBV-969's Dual-Targeting Mechanism
ABBV-969 represents a paradigm shift in ADC design for mCRPC by simultaneously targeting both PSMA and STEAP1 antigens. This dual-targeting approach directly addresses the critical problem of antigen heterogeneity that plagues single-target ADCs in prostate cancer 2, 3, 4.
Key advantages of this design:
- Tumors with low or absent PSMA expression can still be targeted via STEAP1
- Reduces selection pressure for antigen-negative escape variants
- Maintains efficacy across the spectrum of PSMA/STEAP1 expression patterns
- Particularly relevant for heavily pretreated patients where antigen expression may be heterogeneous
Why the Other Options Are Incorrect
Option A is false because ABBV-969 specifically does NOT target PSMA exclusively—its dual-targeting design is its defining feature. PSMA-low patients would actually be expected to benefit through STEAP1 targeting.
Option B is incorrect regarding tam-peli (targeting B7-H3). While B7-H3 is widely expressed in mCRPC 5, 3, the available evidence does not indicate that efficacy correlates tightly with baseline expression levels requiring mandatory IHC pre-screening. B7-H3 expression is relatively ubiquitous in advanced prostate cancer, making it an attractive target without stringent biomarker selection.
Option C overstates toxicity profiles. While interstitial lung disease (ILD) is a recognized class effect of certain ADC payloads (particularly topoisomerase I inhibitors), it is not uniformly a "significant dose-limiting toxicity across all evaluated dose levels" for both agents. The toxicity profiles differ based on payload selection and linker chemistry 5.
Option E incorrectly characterizes toxicity patterns. Both agents can cause hematologic toxicity depending on their specific payloads—this is not exclusive to tam-peli. The statement oversimplifies the complex toxicity profiles that vary with payload chemistry, linker stability, and target expression patterns.
Clinical Implications for Trial Enrollment
For your patient specifically:
ABBV-969 enrollment advantages:
- PSMA-low status is NOT a contraindication—may actually benefit from STEAP1 targeting
- Addresses antigen heterogeneity in heavily pretreated disease
- No requirement for high baseline antigen expression screening
- Designed for the exact clinical scenario your patient presents
Monitoring considerations:
- Standard ADC toxicities: cytopenias, neuropathy, fatigue
- Payload-specific effects depending on cytotoxic agent used
- Regular imaging to assess response given lack of reliable biomarkers in PSMA-low disease
The Broader Context of ADCs in mCRPC
The development of dual-targeted ADCs like ABBV-969 reflects the field's recognition that single-antigen targeting is insufficient in heavily pretreated mCRPC 2, 3, 6. Antigen heterogeneity, lineage plasticity, and treatment-induced selection pressure create populations of tumor cells that escape single-target therapies. Your patient's progression through multiple lines including lutetium PSMA-617 exemplifies this challenge.
Common pitfall to avoid: Do not exclude patients from ADC trials based solely on low expression of a single target antigen when dual-targeted agents are available. The entire rationale for dual-targeting is to overcome this limitation.